KFF June 22, 2021
Rachel Garfield, Rachel Dolan, Elizabeth Williams

Introduction

Several recent policy proposals address the cost of prescription drugs to both consumers and payers. Though attention in current federal actions is largely focused on Medicare and private insurance drug prices, federal legislation also has been recently introduced or enacted that would affect Medicaid prescription drug policy. Most recently, the American Rescue Plan included a provision that would eliminate the Medicaid rebate cap and save $14.5 billion between 2021-2030.

Congress has already started hearings on other legislation to target drug prices and could include such proposals in forthcoming budget reconciliation bills. This brief analyzes leading federal approaches to address Medicaid prescription drug spending, discusses (where available) a range of cost estimates for each policy, and assesses what drives those...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Insurance, Medicaid, Payer, Pharma, Pharma / Biotech
Medicaid Financing Requires Reform: The North Carolina Case Study
GOP plans for Medicaid cuts could face backlash
CMS simplifying Medicaid, CHIP enrollment and renewal processes
Some Medicaid Providers Borrow or Go Into Debt Amid ‘Unwinding’ Payment Disruptions
HHS Announces Medicaid and Medicare Flexibilities, Investigations post-Change Healthcare Cyberattack

Share This Article